Months of life with those we love most is truly priceless
In Chicago, at the annual gathering of oncologists, a small daily pill named daraxonrasib offered something rare in the long struggle against pancreatic cancer: more time. A trial of 500 patients showed that targeting the KRAS gene mutation — present in nearly all pancreatic tumors — nearly doubled median survival compared to standard chemotherapy, while sparing patients many of its harshest effects. For a disease that claims half its sufferers within three months of diagnosis, these months are not statistics but seasons, conversations, and mornings that would otherwise not have come.
- Pancreatic cancer remains one of medicine's most brutal adversaries, killing roughly 10,200 people a year in the UK alone and leaving most patients with almost no time after diagnosis.
- Daraxonrasib's trial results — 13.2 months median survival against chemotherapy's 6.6 — represent an unprecedented leap for a second-line treatment, prompting lead researchers to declare that a 'RAS revolution' has arrived.
- The drug's gentler side-effect profile is itself a disruption: only 1.2% of patients stopped treatment due to adverse effects, compared to 11.2% on chemotherapy, meaning more people could stay the course.
- Cancer charities and clinicians are now pressing UK regulators to fast-track approval and launch domestic trials, warning that the disease's speed leaves no room for slow institutional response.
- The treatment does not halt cancer's advance significantly longer than chemotherapy — progression timelines were nearly identical — but it extends life after that advance, reframing what survival can mean.
A once-daily pill has nearly doubled survival time for people with advanced pancreatic cancer, according to results presented at the American Society of Clinical Oncology meeting in Chicago. Daraxonrasib kept patients alive for a median of 13.2 months, compared to 6.6 months for those on standard chemotherapy — a difference measured not in percentages but in months of life that would otherwise have been lost.
The trial enrolled 500 patients across three continents, all with pancreatic cancer that had spread and already been treated once before. The drug works by silencing the KRAS gene mutation, a corrupted signal present in more than 90 percent of pancreatic tumors that continuously instructs cancer cells to multiply. The survival gain arrived alongside a meaningful reduction in suffering: 43.6 percent of daraxonrasib patients experienced severe side effects versus 57.5 percent on chemotherapy, and just 1.2 percent stopped treatment because of how it made them feel, compared to 11.2 percent in the chemotherapy group.
Rachna Shroff of the University of Arizona Cancer Centre called the results 'landscape-changing,' noting that no second-line treatment had ever produced survival gains of this magnitude. Pancreatic cancer kills approximately 10,200 people annually in the UK, with half of all patients dying within three months of diagnosis — a brutality that makes every additional month consequential.
Pancreatic Cancer UK is now urging regulators to fast-track approval and establish domestic clinical trials, pointing to the National Cancer Plan's commitment to swift access for promising treatments. With KRAS inhibitors advancing worldwide and a disease that moves with unforgiving speed, the charity warns that urgency is not a preference but a necessity.
A once-daily pill has nearly doubled survival time for people with advanced pancreatic cancer, according to results presented at the American Society of Clinical Oncology annual meeting in Chicago. The drug, daraxonrasib, kept patients alive for a median of 13.2 months compared to 6.6 months for those receiving standard chemotherapy—a gain measured not in percentages but in months of life with family, in time that would otherwise have been lost.
The trial enrolled 500 patients across North America, Europe, and Asia. Half received daraxonrasib; half received chemotherapy. All had pancreatic cancer that had spread to other organs and had already been treated before. The drug works by targeting the KRAS gene, a mutated instruction that appears in more than 90 percent of pancreatic tumors and continuously tells cancer cells to multiply. By silencing this signal, daraxonrasib slows the disease's advance.
The survival advantage came with another benefit: fewer people suffered severe side effects. Among those taking daraxonrasib, 43.6 percent experienced serious adverse effects, compared to 57.5 percent on chemotherapy. More tellingly, only 1.2 percent of patients on the new drug stopped treatment because of how it made them feel, whereas 11.2 percent of the chemotherapy group quit for the same reason. The median time before cancer began progressing again was nearly identical in both groups—7.3 months versus 7.2 months—suggesting the drug's advantage lay in extending life rather than halting disease progression longer.
Rachna Shroff, chief of haematology and oncology at the University of Arizona Cancer Centre, called the results "landscape-changing." She noted that the survival gains were unprecedented for a second-line treatment and that the side-effect profile was exactly what researchers had expected. "The RAS revolution is here," she said, referring to a new class of drugs targeting this family of genes.
Pancreatic cancer kills roughly 10,200 people each year in the United Kingdom alone, with approximately 11,500 new cases diagnosed annually. The disease moves with brutal speed: half of all patients die within three months of diagnosis. For those who survive that initial window and progress to advanced stages, the options have been limited and punishing. Anna Jewell, director of services, research, and innovation at Pancreatic Cancer UK, emphasized that these results represent "some of the most exciting developments we have seen in pancreatic cancer for a very long time." She stressed that patients gained not just survival time but the chance to remain under control longer, preserving quality of life alongside quantity of days.
The charity is now calling for the UK to establish its own clinical trials of daraxonrasib and other KRAS inhibitors currently in development worldwide. Jewell urged regulators to fast-track approval of these drugs, citing the National Cancer Plan's commitment to bringing promising treatments to patients quickly. The window for action is narrow: every month matters when the disease itself moves so fast.
Notable Quotes
These results are landscape-changing for metastatic pancreatic cancer patients with a KRAS mutation. The RAS revolution is here, and this study is proof of principle that targeting KRAS in pancreatic cancer is feasible and effective.— Rachna Shroff, chief of haematology/oncology at University of Arizona Cancer Centre
These new treatments targeting KRAS mutations are some of the most exciting developments we have seen in pancreatic cancer for a very long time. Patients were given months more precious time with their loved ones.— Anna Jewell, director of services, research and innovation at Pancreatic Cancer UK
The Hearth Conversation Another angle on the story
Why does this drug work when chemotherapy doesn't, at least not as well?
It's about precision. Chemotherapy is a sledgehammer—it kills fast-dividing cells, which includes cancer but also damages healthy ones. Daraxonrasib is a lock and key. It finds the specific mutation that's driving the cancer and turns it off. In pancreatic cancer, that mutation is almost always KRAS.
So the drug doesn't kill the cancer cells directly?
No. It stops them from getting the signal to grow. It's like cutting the power line instead of demolishing the building. The cancer cells are still there, but they can't expand. That buys time.
The survival numbers—13 months versus 6 months—that's significant, but it's still not a cure.
It's not. But for a disease where half the patients die in three months, an extra six months is profound. That's half a year more with your family. It's the difference between saying goodbye and actually having time to say it.
Why hasn't this been available in the UK yet?
The trial just finished. It's being presented now. Approval takes time, and the UK wants to see the full data. But there's also a push to move faster—cancer charities are arguing that waiting for the usual regulatory timeline costs lives when you're dealing with something this aggressive.
Are there other drugs like this in the pipeline?
Yes. Several KRAS inhibitors are in trials around the world. This is the first to show these kinds of results, but it won't be the last. The real question now is whether the UK will make it easy for patients to access them.